Showing 1321-1330 of 7030 results for "".
Estrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Challenging Cases
https://practicaldermatology.com/conferences/maui-derm-2022/challenging-cases/20054/Seemal R. Desai, MD was part of the Challenging Cases session on everything from new infectious diseases to challenging surgical and aesthetic complications. He says dermatologists play an important role in saving and transforming patients' lives.Hormonal Acne Treatment Options
https://practicaldermatology.com/conferences/maui-derm-2022/hormonal-acne-treatment-options/20053/All acne is hormonal acne, says Julie C. Harper, MD. She discusses her approach to treating acne in preadolescents, adolescents, and male and female patients. From the role of oral contraceptives for women to the new topical clascoterone option, she says there are a number of safe and effective treaDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyCosmetic Surgery Forum: 2021 Recap
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cosmetic-surgery-forum-2021-recap/20032/Cosmetic Surgery Forum founder and director Joel Schlessinger, MD offers an overview of the 2021 conference in Nashville.Protect Your Practice from Fraud, Part 2
https://practicaldermatology.com/topics/practice-management/protect-your-practice-from-fraud-part-2/23606/Part 2 of this series reviews common in-office areas of your practice that may be susceptible to fraud and offers tips for protecting yourself and your practice.An Update on Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/an-update-on-neuromodulators-and-fillers/19983/Suneel Chilukuri, MD discusses daxibotulinumtoxinA and its potential for longer lasting results. He also reviews newly available fillers and specific options for various areas of the face. Plus, he talks about low-cost options and how he’s using devices like SkinPen.Nailed It: Foods for Hair and Nails
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nailed-it-foods-for-hair-and-nails/19932/Zoe Draelos, MD is nuts about natural sources of nutrition and has some berry good news for those interested in alternative to supplements for the hair and nails. Hint: Not everyone needs supplements, she says.DermWireTV: Staff Vaccinations, Dupilumab Data, Rosacea Resource, Sensitive Skin Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-staff-vaccinations-dupilumab-data-rosacea-resource-sensitive-skin-week/19907/Most physicians have had a chance to be vaccinated, but staff may be a different story. Some practices are struggling with policies for mandated staff vaccines. The National Rosacea Society has updated its most popular educational booklet, “Understanding Rosacea.” New data highlight the potential im